Quick Answer
Oruka Therapeutics, Inc. reported Research And Development Expense of $100.64 million for the year ending 2025.
- Oruka Therapeutics, Inc. showed an increase of +34.1% in Research And Development Expense from 2024 to 2025.
- This data is from Oruka Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 12, 2026.
- XBRL data for this metric is available from 2010 to 2025 (16 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 16 years of available data (2010 to 2025), Oruka Therapeutics, Inc.'s Research And Development Expense has grown by 3,140.2%.
- Historical annual values: Fiscal year 2025: $100.64 million | Fiscal year 2024: $75.06 million | Fiscal year 2023: $1.01 million | Fiscal year 2022: $4.75 million | Fiscal year 2021: $13.83 million | Fiscal year 2020: $4.99 million | Fiscal year 2019: $1.83 million | Fiscal year 2018: $4.24 million | Fiscal year 2017: $14.08 million | Fiscal year 2016: $12.35 million | Fiscal year 2015: $7.06 million | Fiscal year 2014: $5.63 million | Fiscal year 2013: $2.93 million | Fiscal year 2012: $1.09 million | Fiscal year 2011: $2.32 million | Fiscal year 2010: $3.11 million.
- Data sourced from SEC EDGAR public filings as of June 21, 2026.
Last verified: